Introduction
Psychotropic polypharmacy is widely used in common practice although there is still a substantial deficit in established knowledge about combination and augmentation therapies. Psychiatric textbooks and international guidelines advise monotherapy wherever possible while reporting a higher risk of adverse drug reactions under polypharmacy.
Material and methods
The AMSP study is a drug safety program that ensures the continuous assessment of severe adverse drug reactions (ADR) in psychiatric inpatients under the natural conditions of routine clinical treatment. Furthermore on two reference days per hospital and per year, the following data are recorded for all patients on the wards under AMSP surveillance: all drugs applied on that day with the daily dosage for psychotropic drugs, ICD diagnosis, age, and sex. Data is stored at the study center in Munich. Due to the increasing number of participating clinics over the years only data of 33 hospitals (5 austrian, 22 german and 6 swiss institutions including university and non-university institutions) who participated since 2003 will be presented. The polypharmacy was primarily due to "multipsychopharmacy", the subscription of multiple classes of psychotropics. Details on type of drug combinations and their relative frequencies will be presented.
Results

Between
Conclusion
Although monotherapy is recommended by international experts, polypharmacy and especially multipsychopharmacy is still gaining ground. Further studies should investigate the most commonly used combinations. Special focus should be put on studies, with the purpose to evaluate assumable positive results of some psychotropic combinations. 
